Sinocelltech Group Full Year 2023 Earnings: Revenues Beat Expectations, EPS Lags

Sinocelltech Group (SHSE:688520) Full Year 2023 Results

Key Financial Results

• Revenue: CN¥1.89b (up 85% from FY 2022).
• Net loss: CN¥396.0m (loss narrowed by 24% from FY 2022).
• CN¥0.89 loss per share (improved from CN¥1.19 loss in FY 2022).

688520 Products In Clinical Trials

• Phase I: 1.
• Phase III: 3.

688520 Post-Clinical Trial Products

• Pre-registration: 3.
• Approved (during full year): 2.

All figures shown in the chart above are for the trailing 12 month (TTM) period

Sinocelltech Group Revenues Beat Expectations, EPS Falls Short

Revenue exceeded analyst estimates by 2.8%. Earnings per share (EPS) missed analyst estimates by 37%.

In the last 12 months, the only revenue segment was Biological Drugs (Drugs and Vaccines) contributing CN¥1.89b. The largest operating expense was Research & Development (R&D) costs, amounting to CN¥1.14b (52% of total expenses). Explore how 688520's revenue and expenses shape its earnings.

Looking ahead, revenue is forecast to grow 31% p.a. on average during the next 2 years, compared to a 23% growth forecast for the Biotechs industry in China.

Performance of the Chinese Biotechs industry.

The company's shares are up 10% from a week ago.

Risk Analysis

It's still necessary to consider the ever-present spectre of investment risk. We've identified 1 warning sign with Sinocelltech Group, and understanding it should be part of your investment process.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.